Is Astria Therapeutics Inc (ATXS) overvalued? · rev $706.0K
Astria Therapeutics Inc (ATXS) is a biotechnology company listed on US.
This page asks whether Astria Therapeutics Inc (ATXS) looks expensive on cached numbers — not a short thesis.
Latest reported ATXS revenue for 2025-09-30 was $706.0K. Net income was -$98.4M. ATXS currently screens at market cap $382.1M.
ATXS currently screens at market cap $382.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ATXS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ATXS stock page for the full model, not this heading.
Not investment advice.